Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issues
This issue
23-4
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
23-4
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Index of Authors
Author #32545
advertisement
Zeng L
17
Showing records 1 to 17 |
Display all abstracts from
Zeng L
107646
Integrated aqueous humor ceRNA and miRNA-TF-mRNA network analysis reveals potential molecular mechanisms governing primary open-angle glaucoma pathogenesis
Wang X
Indian Journal of Ophthalmology
2023; 71: 553-559
108376
Outcomes of Partial Versus Complete Goniotomy With or Without Phacoemulsification for Primary Open Angle Glaucoma: A Multicenter Study
Song Y
Journal of Glaucoma
2023; 32: 563-568
108386
Rapamycin suppresses neuroinflammation and protects retinal ganglion cell loss after optic nerve crush
Wang F; Song Y
International immunopharmacology
2023; 119: 110171
108376
Outcomes of Partial Versus Complete Goniotomy With or Without Phacoemulsification for Primary Open Angle Glaucoma: A Multicenter Study
Zhu X
Journal of Glaucoma
2023; 32: 563-568
107646
Integrated aqueous humor ceRNA and miRNA-TF-mRNA network analysis reveals potential molecular mechanisms governing primary open-angle glaucoma pathogenesis
Chen M; Liu L
Indian Journal of Ophthalmology
2023; 71: 553-559
108386
Rapamycin suppresses neuroinflammation and protects retinal ganglion cell loss after optic nerve crush
Liu P
International immunopharmacology
2023; 119: 110171
107646
Integrated aqueous humor ceRNA and miRNA-TF-mRNA network analysis reveals potential molecular mechanisms governing primary open-angle glaucoma pathogenesis
Zeng L
Indian Journal of Ophthalmology
2023; 71: 553-559
108386
Rapamycin suppresses neuroinflammation and protects retinal ganglion cell loss after optic nerve crush
Ma F
International immunopharmacology
2023; 119: 110171
108376
Outcomes of Partial Versus Complete Goniotomy With or Without Phacoemulsification for Primary Open Angle Glaucoma: A Multicenter Study
Shu J
Journal of Glaucoma
2023; 32: 563-568
108386
Rapamycin suppresses neuroinflammation and protects retinal ganglion cell loss after optic nerve crush
Peng Z
International immunopharmacology
2023; 119: 110171
108376
Outcomes of Partial Versus Complete Goniotomy With or Without Phacoemulsification for Primary Open Angle Glaucoma: A Multicenter Study
Dang G; Zhou W
Journal of Glaucoma
2023; 32: 563-568
108386
Rapamycin suppresses neuroinflammation and protects retinal ganglion cell loss after optic nerve crush
Pang Y; Hu H
International immunopharmacology
2023; 119: 110171
108376
Outcomes of Partial Versus Complete Goniotomy With or Without Phacoemulsification for Primary Open Angle Glaucoma: A Multicenter Study
Sun L; Li F
Journal of Glaucoma
2023; 32: 563-568
108386
Rapamycin suppresses neuroinflammation and protects retinal ganglion cell loss after optic nerve crush
Zeng L; Luo H
International immunopharmacology
2023; 119: 110171
108376
Outcomes of Partial Versus Complete Goniotomy With or Without Phacoemulsification for Primary Open Angle Glaucoma: A Multicenter Study
Lin F
Journal of Glaucoma
2023; 32: 563-568
108386
Rapamycin suppresses neuroinflammation and protects retinal ganglion cell loss after optic nerve crush
Zhang X
International immunopharmacology
2023; 119: 110171
108376
Outcomes of Partial Versus Complete Goniotomy With or Without Phacoemulsification for Primary Open Angle Glaucoma: A Multicenter Study
Liang X; Wang Z; Zhang Y; Chen W; Zeng L; Tang L; Xie L; Lam DSC; Wang N; Barton K; Weinreb RN; Zhang X;
Journal of Glaucoma
2023; 32: 563-568
Issue
23-4
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept